Why the study?
Does intravenous administration of streptokinase induce an acute phase reaction in patients with myocardial infarction?
Does intravenous administration of streptokinase induce an acute phase reaction in patients with myocardial infarction?
Intravenous streptokinase therapy for myocardial infarction induces a marked acute phase reaction, which may paradoxically increase the risk of thrombosis.
Answers are grounded in this paper and cite their sources.
Streptokinase may heighten post-MI thrombosis risk via acute-phase reactants; Level 5 data leave this hypothesis-generating and unconfirmed.
Summary SK-therapy regularly is followed by a marked elevation of those plasma proteins known as “acute phase reactants” (α 1-antitrypsin, orosomucoid, β 1 C-globulin, ceruloplasmin). In short-time therapy of myocardial infarction also a transitory presence of CRP is demonstrable. After an initial decrease of fibrinogen caused by fibrinogenolysis, this protein increases significantly too. The high level of α 1-antitrypsin (slow reacting antiplasmin) and/or fibrinogen may lead to rheological consequences which may result in thrombosis.
No takes yet. Share an insight, caveat, or question.
Spöttl et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: